Larry W Hawk1, Rebecca L Ashare2, Jessica D Rhodes3, Jason A Oliver4, Kenneth Michael Cummings5, Martin C Mahoney6. 1. Department of Psychology, State University of New York at Buffalo, Buffalo, NY; Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, NY; lhawk@buffalo.edu. 2. Department of Psychology, State University of New York at Buffalo, Buffalo, NY; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 3. Department of Psychology, State University of New York at Buffalo, Buffalo, NY; Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA; 4. Department of Psychology, State University of New York at Buffalo, Buffalo, NY; Department of Psychiatry, Yale University, New Haven, CT; 5. Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, NY; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC. 6. Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, NY;
Abstract
INTRODUCTION: Understanding the mechanisms by which bupropion promotes smoking cessation may lead to more effective treatment. To the extent that reduced smoking reinforcement is one such mechanism, a longer duration of pre quit bupropion treatment should promote extinction of smoking behavior. We evaluated whether 4 weeks of pre quit bupropion (extended run-in) results in greater pre quit reductions in smoking rate and cotinine and, secondarily, greater short-term abstinence, than standard 1 week of pre quit bupropion (standard run-in). METHODS:Adult smokers (n = 95; 48 females) were randomized to a standard run-in group (n = 48; 3-week placebo, then 1-week bupropion pre quit) or an extended run-in group (4-week pre quit bupropion; n = 47). Both groups received group behavioral counseling and 7 weeks of post quit bupropion. Smoking rate (and craving, withdrawal, and subjective effects) was collected daily during the pre quit period; biochemical data (cotinine and carbon monoxide) were collected at study visits. RESULTS: During the pre quit period, the extended run-in group exhibited a greater decrease in smoking rate, compared to the standard run-in group, interaction p = .03. Cigarette craving and salivary cotinine followed a similar pattern, though the latter was evident only among women. Biochemically verified 4-week continuous abstinence rates were higher in the extended run-in group (53%) than the standard run-in group (31%), p = .033. CONCLUSIONS: The extended use of bupropion prior to a quit attempt reduces smoking behavior during the pre quit period and improved short-term abstinence rates. The data are consistent with an extinction-of-reinforcement model and support further investigation of extended run-in bupropion therapy for smoking cessation.
RCT Entities:
INTRODUCTION: Understanding the mechanisms by which bupropion promotes smoking cessation may lead to more effective treatment. To the extent that reduced smoking reinforcement is one such mechanism, a longer duration of pre quit bupropion treatment should promote extinction of smoking behavior. We evaluated whether 4 weeks of pre quit bupropion (extended run-in) results in greater pre quit reductions in smoking rate and cotinine and, secondarily, greater short-term abstinence, than standard 1 week of pre quit bupropion (standard run-in). METHODS: Adult smokers (n = 95; 48 females) were randomized to a standard run-in group (n = 48; 3-week placebo, then 1-week bupropion pre quit) or an extended run-in group (4-week pre quit bupropion; n = 47). Both groups received group behavioral counseling and 7 weeks of post quit bupropion. Smoking rate (and craving, withdrawal, and subjective effects) was collected daily during the pre quit period; biochemical data (cotinine and carbon monoxide) were collected at study visits. RESULTS: During the pre quit period, the extended run-in group exhibited a greater decrease in smoking rate, compared to the standard run-in group, interaction p = .03. Cigarette craving and salivary cotinine followed a similar pattern, though the latter was evident only among women. Biochemically verified 4-week continuous abstinence rates were higher in the extended run-in group (53%) than the standard run-in group (31%), p = .033. CONCLUSIONS: The extended use of bupropion prior to a quit attempt reduces smoking behavior during the pre quit period and improved short-term abstinence rates. The data are consistent with an extinction-of-reinforcement model and support further investigation of extended run-in bupropion therapy for smoking cessation.
Authors: Matthew I Palmatier; Melissa E Levin; Kara L Mays; Eric C Donny; Anthony R Caggiula; Alan F Sved Journal: Psychopharmacology (Berl) Date: 2009-09-17 Impact factor: 4.530
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Xiu Liu; Anthony R Caggiula; Matthew I Palmatier; Eric C Donny; Alan F Sved Journal: Psychopharmacology (Berl) Date: 2007-10-12 Impact factor: 4.530
Authors: Megan E Piper; Jessica W Cook; Tanya R Schlam; Douglas E Jorenby; Stevens S Smith; Linda M Collins; Robin Mermelstein; David Fraser; Michael C Fiore; Timothy B Baker Journal: Ann Behav Med Date: 2018-09-13
Authors: Megan E Piper; Jessica W Cook; Tanya R Schlam; Stevens S Smith; Daniel M Bolt; Linda M Collins; Robin Mermelstein; Michael C Fiore; Timothy B Baker Journal: Drug Alcohol Depend Date: 2016-11-24 Impact factor: 4.492
Authors: Thomas H Brandon; Marina Unrod; David J Drobes; Steven K Sutton; Larry W Hawk; Vani N Simmons; Karen O Brandon; Richard G Roetzheim; Lauren R Meltzer; Ralph R Miller; Shawn P Cahill Journal: Nicotine Tob Res Date: 2018-09-04 Impact factor: 4.244